Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric or Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07603349
What this trial is testing

Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University 405
Large-scale testing (Phase 3)Study completedNCT02314117
What this trial is testing

Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Who this might be right for
Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Eli Lilly and Company 645
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Testing effectiveness (Phase 2)Study completedNCT00938470
What this trial is testing

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionEsophageal CancerGastric Cancer
Alliance for Clinical Trials in Oncology 73
Testing effectiveness (Phase 2)Study completedNCT00526110
What this trial is testing

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

Who this might be right for
Gastrointestinal Diseases
M.D. Anderson Cancer Center 98
Testing effectiveness (Phase 2)Study completedNCT00514020
What this trial is testing

Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer
Vanderbilt-Ingram Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Testing effectiveness (Phase 2)Ended earlyNCT04933227
What this trial is testing

Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Who this might be right for
Stomach NeoplasmsGastric CancerGastroesophageal Junction Adenocarcinoma
Hoffmann-La Roche 29
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Testing effectiveness (Phase 2)UnknownNCT05122091
What this trial is testing

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Who this might be right for
Gastric CancerGastroEsophageal CancerFruquintinib+1 more
Guangxi Medical University 53
Testing effectiveness (Phase 2)Looking for participantsNCT07102901
What this trial is testing

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric CancerMetastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 351
Testing effectiveness (Phase 2)Looking for participantsNCT07110571
What this trial is testing

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Who this might be right for
Gastric CancerGastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 200
Testing effectiveness (Phase 2)Looking for participantsNCT05482893
What this trial is testing

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Who this might be right for
Gastric or Gastroesophageal Junction AdenocarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)
Phanes Therapeutics 258
Testing effectiveness (Phase 2)Active Not RecruitingNCT06939452
What this trial is testing

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia 37
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685704
What this trial is testing

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
Zhifeng Zhao, PhD 46
Testing effectiveness (Phase 2)Study completedNCT02689284
What this trial is testing

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerStomach CancerEsophageal Cancer
MacroGenics 95
Large-scale testing (Phase 3)Looking for participantsNCT07392892
What this trial is testing

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Who this might be right for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal AdenocarcinomaMetastatic Gastric CancerGastroesophageal Junction Cancer+1 more
Pfizer 840
Testing effectiveness (Phase 2)UnknownNCT03817411
What this trial is testing

Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

Who this might be right for
Gastric Cancer
Taizhou EOC Pharma Co., Ltd. 90
Early research (Phase 1)Ended earlyNCT02862535
What this trial is testing

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Gilead Sciences 36
Next Page
507